Oligonucleotide therapeutics analytical development support services from the initial characterisation and CMC through to long term quality control.
Analysis and development of oligonucleotide therapies such as antisense oligonucleotides (ASOs) and aptamers, or RNA-based therapeutics (e.g. siRNAs, mRNA, miRNA) involve a strategic approach to formulation and analytical development. The method of production can impact purity as well as the secondary structure – which in turn can impact stability and solubility.
The structural properties of these products present many challenges in both synthesis and analysis. With a growing development pipeline, the safety, efficacy, purity, stability, and activity of these products are a concern for developers – particularly in the absence of specific, dedicated regulatory guidance.
Intertek Pharmaceutical Services has supported oligonucleotide drug development from the inception of the therapeutic class. Our analytical scientists support product development, from quality control testing of amidite starting materials and early-stage product characterisation through to GMP batch release testing for either single strand or duplex products. We conduct integrated stability programs for oligonucleotides incorporating ICH storage and testing to cGMP. We have specialist expertise in inhalation drug product development, and extractable and leachables studies and our bioanalysis experts design and manage strategic work programs to support your preclinical and clinical development.
With experience in the strategic application of orthogonal analytical techniques for oligonucleotide therapeutics and heritage of supporting GMP manufacturing and regulatory submission requirements, our expertise supports your development from initial characterisation and CMC through to long-term quality control.
Confirm identity, determine safety, efficacy, purity, quality, and strength and identify and quantify contaminants
Supporting therapeutic and vaccine development to assess clinical translation efficiency and immunogenicity
Brochure: mRNA Characterisation Services
Physico-chemical characterisation and release testing services for nanoparticles, viral vectors, liposomes and lipid nano-particles
Immunochemistry and biomarker services for bioanalytical studies supporting preclinical and clinical development
Extractables & Leachables Studies
Assess and quantify risk associated with potential leachable impurities from container closures, process equipment or packaging
Customised cGMP cell-based potency assays to quantify the biological activity of oligonucleotides
GMP stability studies and ICH storage services supporting development, batch release and quality control testing
Development services including formulation development, GMP testing and clinical trial material manufacturing
COVID-19 VACCINE OR THERAPEUTIC TESTING & DEVELOPMENT SUPPORT
IMMEDIATE QUESTION? Ask our experts now
FACTSHEET: COVID-19 Vaccine or Therapeutic Testing & Development Outsourcing
ARTICLE: Repurposing Vaccines for Intranasal Development
WEBINAR: Quality Control Strategy for Vaccine Development
WEBINAR: Repurposing Drugs for Inhaled Delivery
eBOOK: Contingency Outsourcing Solutions
Pharmaceutical News & Events
- Determination of Particles in Pharmaceuticals - Article
- Discover our Audit Live Tool for direct access to our scheduled audits
- Extractables/Leachables Lab Tour - Request access
- Medical Device Extractables & Leachables Studies
- Glycosylation Analytical Approaches for Antibody Therapeutics
- Rapid Determination of Low/Trace Level Benzene in Pharmaceutical Excipients and Finished Products
- mRNA Analytics: Capping Efficiency, Sequencing, Poly-A Tail, dsRNA
WEBINAR: Designing a QC Strategy for mRNA Vaccines
CASE STUDY: CMC Considerations for mRNA Based Therapies
SPECIAL REPORT: Analytical Challenges - Characterisation of Oligonucleotide Therapeutics
PRESENTATION: Data Analysis for CMC Testing of Oligonucleotides
CASE STUDY: Determination of Melting Temperature for Oligonucleotide Duplexes using NMR
CASE STUDY: Identification Testing by Accurate Mass and MS/MS Sequencing
ARTICLE: Physicochemical Properties of Liposomal Advanced Drug Delivery Technologies
CASE STUDY: CMC Considerations for mRNA Based Therapies